Venlafaxine, serotonin syndrome, and differential diagnoses

Journal of Clinical Psychopharmacology

Volumn 25, Issue 1, 2005, Pages 101-102

  Montanes Rada F ^a,b   Bilbao Garay, J ^a   De Lucas Taracena, M T ^b,c   Ortiz Ortiz, M E ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c Centro de Salud Mental Usera   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; LORAZEPAM; MIANSERIN; MIRTAZAPINE; VENLAFAXINE;

ADULT; ANAMNESIS; BLOOD ANALYSIS; BODY POSTURE; CASE REPORT; CATATONIA; CLINICAL FEATURE; CONFUSION; DEFENSE MECHANISM; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DRUG SUBSTITUTION; FEMALE; HUMAN; LETTER; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; SEROTONIN SYNDROME; TREATMENT WITHDRAWAL; URINALYSIS;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CATATONIA; CYCLOHEXANOLS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME; SEROTONIN SYNDROME;

EID: 12344279784     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000150236.45361.e1     Document Type: Letter

References (4)

1. Mann SC, Caroff SN, Keck PE, et al. Neuroleptic Malignant Syndrome and Related Conditions. 2nd ed. Washington, DC: American Psychiatric Press, 2003.
2. Nimgamada SR, Ryan DH, Atkin SL. Neuroleptic syndrome after venlafaxine. Lancet. 2000;354:289-290.
3. Maj J, Rogoz Z. Pharmacological effects of venlafaxine, a new antidepressant, given repeatedly, on the alpha 1-adrenergic, dopamine and serotonin systems. J Neural Transmission. 1999;106:197-211.
4. Stembach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705-713.